<DOC>
	<DOCNO>NCT02801357</DOCNO>
	<brief_summary>The purpose study evaluate relative exposure lofexidine major metabolite subject seek buprenorphine dose reduction .</brief_summary>
	<brief_title>Study Evaluate Exposures Lofexidine Its Major Metabolites Subjects Seeking Buprenorphine Dose Reduction</brief_title>
	<detailed_description>This Phase 1 , open-label , inpatient study male female subject seek least 4 mg reduction buprenorphine maintenance dose . The purpose study assess relative exposure lofexidine 3 major metabolite subject taper buprenorphine maintenance treatment . Lofexidine alpha-2 adrenergic agonist development treatment acute withdrawal short-acting opioids .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Have current dependency subject maintain daily dose 8 24 mg buprenorphine seek reduction buprenorphine dose least 4 mg. Urine toxicology screen positive buprenorphine Screening . Agree collection blood sample genotyping CYP2D6 metabolizer status . If female childbearing potential , subject must use birth control least 30 day must agree use acceptable form birth control least 30 day last dose study drug . If male , must agree use acceptable form birth control throughout entire study period 90 day last dose study drug . Must donate sperm 90 day last dose study drug . Be female subject pregnant lactating . Have serious medical illness control . Have participate investigational drug study within past 30 day . Received drug know strong , moderate weak inhibitor cytochrome P450 ( CYP ) enzymes CYP1A2 , CYP2C19 , CYP2D6 , within 14 day 5 halflives ( whichever ) Day 1 . Abnormal cardiovascular exam Screening . Subjects require follow exclude : Tricyclic antidepressant , may reduce efficacy imidazoline derivative ; Betareceptor blocker , avoid risk excessive bradycardia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>substance withdrawal syndrome</keyword>
	<keyword>opiate addiction</keyword>
	<keyword>opiate dependence</keyword>
	<keyword>opioid withdrawal syndrome</keyword>
	<keyword>buprenorphine</keyword>
</DOC>